FULCRUM THERAPEUTICS, INC. Financing Cash Flow
FULCRUM THERAPEUTICS, INC. (FULC) reported Financing Cash Flow of $44.00 thousand for the 6-month period ending 2026-06-30, per its S-4 filed 2026-09-02.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-09-02
- FULCRUM THERAPEUTICS, INC. net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was $356.00K, a 18.27% increase year-over-year.
- FULCRUM THERAPEUTICS, INC. net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was -$312.00K.
- FULCRUM THERAPEUTICS, INC. net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was $168.30M, a 202673.49% increase year-over-year.
- FULCRUM THERAPEUTICS, INC. net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was $64.00K, a 89.92% decline year-over-year.
- FULCRUM THERAPEUTICS, INC. net cash provided by (used in) financing activities for fiscal 2023 was $118.12M, a 40.08% increase from fiscal 2022.
- FULCRUM THERAPEUTICS, INC. net cash provided by (used in) financing activities for fiscal 2022 was $84.32M, a 54.79% decline from fiscal 2021.
- FULCRUM THERAPEUTICS, INC. net cash provided by (used in) financing activities for fiscal 2021 was $186.51M, a 162.20% increase from fiscal 2020.
- FULCRUM THERAPEUTICS, INC. net cash provided by (used in) financing activities for fiscal 2020 was $71.13M, a 10.55% increase from fiscal 2019.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $356.00K derived: S-4 6 month − 10-Q 3 month · filed 2026-09-02 | $44.00K S-4 · filed 2026-09-02 | $168.35M derived: sum of 3 quarters · filed 2026-09-02 | $168.41M derived: sum of 4 quarters · filed 2026-09-02 |
| 2026-03-31 | -$312.00K 10-Q · filed 2026-04-27 | $167.99M derived: sum of 2 quarters · filed 2026-09-02 | $168.05M derived: sum of 3 quarters · filed 2026-09-02 | $168.35M derived: sum of 4 quarters · filed 2026-09-02 |
| 2025-12-31 | $168.30M derived: S-4 12 month − 10-Q 9 month · filed 2026-09-02 | $168.37M derived: sum of 2 quarters · filed 2026-09-02 | $168.67M derived: sum of 3 quarters · filed 2026-09-02 | $168.67M S-4 · filed 2026-09-02 |
| 2025-09-30 | $64.00K derived: 10-Q 9 month − S-4 6 month · filed 2025-10-29 | $365.00K derived: sum of 2 quarters · filed 2026-09-02 | $365.00K 10-Q · filed 2025-10-29 | $448.00K derived: sum of 4 quarters · filed 2026-09-02 |
| 2025-06-30 | $301.00K derived: S-4 6 month − 10-Q 3 month · filed 2026-09-02 | $301.00K S-4 · filed 2026-09-02 | $384.00K derived: sum of 3 quarters · filed 2026-09-02 | $1.02M derived: sum of 4 quarters · filed 2026-09-02 |
| 2025-03-31 | $0.00 10-Q · filed 2026-04-27 | $83.00K derived: sum of 2 quarters · filed 2026-09-02 | $718.00K derived: sum of 3 quarters · filed 2026-09-02 | $1.09M derived: sum of 4 quarters · filed 2026-09-02 |
| 2024-12-31 | $83.00K derived: S-4 12 month − 10-Q 9 month · filed 2026-09-02 | $718.00K derived: sum of 2 quarters · filed 2026-09-02 | $1.09M derived: sum of 3 quarters · filed 2026-09-02 | $2.75M S-4 · filed 2026-09-02 |
| 2024-09-30 | $635.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-29 | $1.01M derived: sum of 2 quarters · filed 2025-10-29 | $2.66M 10-Q · filed 2025-10-29 | $2.95M derived: sum of 4 quarters · filed 2025-10-29 |
| 2024-06-30 | $377.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-29 | $2.03M 10-Q · filed 2025-07-29 | $2.31M derived: sum of 3 quarters · filed 2025-07-29 | $2.31M derived: sum of 4 quarters · filed 2025-07-29 |
| 2024-03-31 | $1.65M 10-Q · filed 2025-05-01 | $1.94M derived: sum of 2 quarters · filed 2025-05-01 | $1.94M derived: sum of 3 quarters · filed 2025-05-01 | $2.08M derived: sum of 4 quarters · filed 2025-05-01 |
| 2023-12-31 | $287.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $287.00K derived: sum of 2 quarters · filed 2025-02-25 | $429.00K derived: sum of 3 quarters · filed 2025-02-25 | $118.12M 10-K · filed 2025-02-25 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $142.00K derived: sum of 2 quarters · filed 2024-11-13 | $117.83M 10-Q · filed 2024-11-13 | $118.05M derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | $142.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-07-31 | $117.83M 10-Q · filed 2024-07-31 | $118.05M derived: sum of 3 quarters · filed 2024-07-31 | $199.00M derived: sum of 4 quarters · filed 2024-07-31 |
| 2023-03-31 | $117.69M 10-Q · filed 2024-05-13 | $117.91M derived: sum of 2 quarters · filed 2024-05-13 | $198.86M derived: sum of 3 quarters · filed 2024-05-13 | $201.67M derived: sum of 4 quarters · filed 2024-05-13 |
| 2022-12-31 | $218.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $81.16M derived: sum of 2 quarters · filed 2024-02-27 | $83.97M derived: sum of 3 quarters · filed 2024-02-27 | $84.32M 10-K · filed 2024-02-27 |
| 2022-09-30 | $80.95M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $83.76M derived: sum of 2 quarters · filed 2023-11-07 | $84.11M 10-Q · filed 2023-11-07 | $85.00M derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | $2.81M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $3.16M 10-Q · filed 2023-08-03 | $4.05M derived: sum of 3 quarters · filed 2023-08-03 | $141.95M derived: sum of 4 quarters · filed 2023-08-03 |
| 2022-03-31 | $348.00K 10-Q · filed 2023-05-15 | $1.24M derived: sum of 2 quarters · filed 2023-06-26 | $139.14M derived: sum of 3 quarters · filed 2023-06-26 | $139.35M derived: sum of 4 quarters · filed 2023-06-26 |
| 2021-12-31 | $891.00K derived: 10-K/A 12 month − 10-Q 9 month · filed 2023-06-26 | $138.79M derived: sum of 2 quarters · filed 2023-06-26 | $139.00M derived: sum of 3 quarters · filed 2023-06-26 | $186.51M 10-K/A · filed 2023-06-26 |
| 2021-09-30 | $137.90M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $138.11M derived: sum of 2 quarters · filed 2022-11-08 | $185.62M 10-Q · filed 2022-11-08 | $191.87M derived: sum of 4 quarters · filed 2023-06-26 |
| 2021-06-30 | $209.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $47.71M 10-Q · filed 2022-08-11 | $53.97M derived: sum of 3 quarters · filed 2023-06-26 | $53.88M derived: sum of 4 quarters · filed 2023-06-26 |
| 2021-03-31 | $47.50M 10-Q · filed 2022-05-09 | $53.76M derived: sum of 2 quarters · filed 2023-06-26 | $53.68M derived: sum of 3 quarters · filed 2023-06-26 | $118.36M derived: sum of 4 quarters · filed 2023-06-26 |
| 2020-12-31 | $6.25M derived: 10-K/A 12 month − 10-Q 9 month · filed 2023-06-26 | $6.17M derived: sum of 2 quarters · filed 2023-06-26 | $70.86M derived: sum of 3 quarters · filed 2023-06-26 | $71.13M 10-K/A · filed 2023-06-26 |
| 2020-09-30 | -$83.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $64.60M derived: sum of 2 quarters · filed 2021-11-04 | $64.88M 10-Q · filed 2021-11-04 | $64.60M derived: sum of 4 quarters · filed 2023-06-23 |
| 2020-06-30 | $64.69M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-10 | $64.96M 10-Q · filed 2021-08-10 | $64.68M derived: sum of 3 quarters · filed 2023-06-23 | $129.88M derived: sum of 4 quarters · filed 2023-06-23 |
| 2020-03-31 | $274.00K 10-Q · filed 2021-05-06 | -$7.00K derived: sum of 2 quarters · filed 2023-06-23 | $65.19M derived: sum of 3 quarters · filed 2023-06-23 | $64.66M derived: sum of 4 quarters · filed 2023-06-23 |
| 2019-12-31 | -$281.00K derived: 10-K/A 12 month − 10-Q 9 month · filed 2023-06-23 | $64.92M derived: sum of 2 quarters · filed 2023-06-23 | $64.39M derived: sum of 3 quarters · filed 2023-06-23 | $64.34M 10-K/A · filed 2023-06-23 |
| 2019-09-30 | $65.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-10 | $64.67M derived: sum of 2 quarters · filed 2020-11-10 | $64.62M 10-Q · filed 2020-11-10 | $64.53M derived: sum of 4 quarters · filed 2020-11-10 |
| 2019-06-30 | -$529.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-11 | -$576.00K 10-Q · filed 2020-08-11 | -$666.00K derived: sum of 3 quarters · filed 2020-08-11 | $79.16M derived: sum of 4 quarters · filed 2020-08-11 |
| 2019-03-31 | -$47.00K 10-Q · filed 2020-05-13 | -$137.00K derived: sum of 2 quarters · filed 2020-05-13 | $79.69M derived: sum of 3 quarters · filed 2020-05-13 | |
| 2018-12-31 | -$90.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-05 | $79.73M derived: sum of 2 quarters · filed 2020-03-05 | $105.03M 10-K · filed 2020-03-05 | |
| 2018-09-30 | $79.83M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-14 | $105.11M 10-Q · filed 2019-11-14 | ||
| 2018-06-30 | $25.29M 10-Q · filed 2019-08-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |